CASE REPORT

Loeffler endocarditis with intracardiac thrombus: case report and literature review

Qian Zhang†, Daoyuan Si†, Zhongfan Zhang and Wenqi Zhang*

Abstract

Background: Loeffler endocarditis is a relatively rare and potentially life-threatening heart disease. This study aimed to identify the characteristic features of Loeffler endocarditis with intracardiac thrombus on a background of hypereosinophilic syndrome (HES).

Case presentation: We described a 57-year-old woman with Loeffler endocarditis and intracardiac thrombus initially presenting with neurological symptoms, who had an embolic stroke in the setting of HES. After cardiac magnetic resonance (CMR), corticosteroids and warfarin were administered to control eosinophilia and thrombi, respectively. During a 10-month follow-up, the patient performed relatively well, with no adverse events. We also systematically searched PubMed and Embase for cases of Loeffler endocarditis with intracardiac thrombus published until July 2021. A total of 32 studies were eligible and included in our analysis. Further, 36.4% of recruited patients developed thromboembolic complications, and the mortality rate was relatively high (27.3%). CMR was a powerful noninvasive modality in providing diagnostic and follow-up information in these patients. Steroids were administered in 81.8% of patients, achieving a rapid decrease in the eosinophil count. Also, 69.7% of patients were treated with anticoagulant therapy, and the thrombus was completely resolved in 42.4% of patients. Heart failure and patients not treated with anticoagulation were associated with poor outcomes.

Conclusions: Cardiac involvement in HES, especially Loeffler endocarditis with intracardiac thrombus, carries a pessimistic prognosis and significant mortality. Early steroids and anticoagulation therapy may be beneficial once a working diagnosis is established. Further studies are needed to provide evidence-based evidence for managing this uncommon manifestation of HES.

Keywords: Case report, Eosinophilia, Hypereosinophilic syndrome, Intracardiac thrombus, Loeffler endocarditis

Background

Hypereosinophilic syndrome (HES) is a rare disorder characterized by the elevation of blood eosinophil count (> 1.5 x 10^9/L) and multiple-organ involvement directly attributable to eosinophilia [1]. Loeffler endocarditis involves the abnormal infiltration of eosinophils into the endomyocardium, with subsequent tissue damage and fibrosis resulting from eosinophil degranulation, eventually leading to impaired diastolic function and restrictive ventricular filling [2]. It is divided into three pathological stages: necrotic stage, thrombotic stage, and fibrotic stage [3]. Notably, systemic thromboembolic events after mural thrombus formation and cardiac manifestations are considered to be common causes of morbidity and mortality in HES [4]. Considering the less recognized and high in-hospital mortality of patients with Loeffler endocarditis, data regarding their clinical presentations, courses, and outcomes remain uncertain. Furthermore, some evidence supports the effectiveness of steroids [5]. However, the guidelines and consensus statements regarding the treatment of Loeffler endocarditis...
are not clear. Therefore, this study aimed to present an unusual case of Loeffler endocarditis and intracardiac thrombus that caused cerebral embolic infarctions, and to conduct a systematic review on published cases of Loeffler endocarditis with intracardiac thrombus, summarizing clinical manifestations, diagnosis, treatments, and outcomes.

**Case presentation**

A 57-year-old woman with a known history of asthma and rheumatoid arthritis was admitted to the hospital after presenting with a headache and dyspnea for 1 week. The neurological examination showed vague speech, mild dysarthria, and limb muscle strength level 3. Her brain magnetic resonance imaging showed multifocal acute-to-subacute ischemic lesions widely distributed over the bilateral cerebellar hemispheres and thalamus and parenchymal hemorrhage (Fig. 1). The initial laboratory findings were as follows: the white blood cell count was $20.43 \times 10^9$ (normal range, $4–10 \times 10^9$/L), with increased peripheral eosinophilia at $12.04 \times 10^9$/L (normal range, $0.05–0.50 \times 10^9$/L). Other inflammatory parameters showed an increased erythrocyte sedimentation rate of 79 mm/h (normal range, 0–20 mm/h) and a C-reactive protein level of 95.4 mg/L (normal range, 0–8 mg/L). The patient was also positive for the

![Fig. 1 Brain magnetic resonance imaging. A Diffuse-weighted image (DWI), B apparent diffusion coefficient (ADC) map, C T2-weighted image, and D fluid attenuated inversion recovery (FLAIR) image. Multifocal lesions of high intensity on DWI and ADC maps showed low values. There were multiple T2 high signal lesions in bilateral cerebral white matter](image-url)
anti-antineutrophilic perinuclear antibody (pANCA). Other specific markers related to autoimmune diseases, such as anti-dsDNA and anti-Sm, rheumatoid factor were all negative. Her travel history was unremarkable. Her hospital course was further complicated by severe shortness of breath and elevated cardiac enzyme levels (cTnI: 14.10 ng/mL, CK-MB: 41.9 U/L, NT-proBNP: 28,700 ng/mL), which prompted an extensive cardiac workup. The electrocardiogram showed T-wave inversions in leads II, III, and aVF (Fig. 2). Two-dimensional echocardiography (Fig. 3A) showed that the systolic function of the heart was within the normal range, which was found to be 59% by the Simpson method. A thickened left ventricular (LV) endocardium with markedly solid echo could be seen, and a diagnosis of LV thrombus formation was suggested. Severe mitral regurgitation

![Fig. 2 Electrocardiogram: normal sinus rhythm, T wave inversion in leads II, III, aVF, V3, V4, V5, V6](image)

![Fig. 3 A Apical four-chamber view of the transthoracic echocardiogram showing thickened left ventricular endocardium and left ventricular thrombus formation (red circle). B Ten-month follow-up echocardiographic imaging after treatment showing thickening of the left ventricular apex and suspicion of apical thrombus](image)
and moderate tricuspid regurgitation were noted. A small amount of pericardial fluid was also present (4.6 mm). We further excluded other causes of eosinophilia, such as malignancy, autoimmune diseases, and drug reactions. The parasites were negative in stool culture. In the peripheral blood smear, most of the granulocytes were normal, with no clonal proliferation or primordial cells. Further diagnostic clarification was required. The cardiac magnetic resonance (CMR) confirmed the presence of a thrombus measuring approximately $1.5 \times 1.7$ cm in the apex of the LV, which, we believed, was the source of cerebral embolization. Gadolinium-enhanced CMR showed striated delayed enhancement between the apex and the papillary muscles restricted to the endocardium, with decreased diastolic function (Fig. 4), which was consistent with extensive endomyocardial fibrosis. Endocardial biopsy was recommended as the diagnostic gold standard to verify the histopathologic features. However, considering the risk of this invasive operation, the patient refused.

Based on the diagnosis of Loeffler endocarditis with LV thrombus, an intravenous bolus of a corticosteroid [prednisolone 1 mg/(kg·day)] was initiated, followed by 40 mg per day orally, which was prescribed as a definitive line of therapy. The blood tests showed significantly decreased eosinophil counts and percentages after another 2 days, along with a normalized cTnT level. The patient was treated with rivaroxaban to dissolve the thrombus, but the thrombus did not shrink after 3 months. Then, warfarin was added as antithrombotic therapy until follow-up. She was doing relatively well, and no adverse events occurred during a 10-month follow-up period. The echocardiography showed apical hypertrophy, and a suspected thrombus still existed (Fig. 3B). Therefore, CMR (Fig. 5) was repeated, which revealed the complete resolution of

![Fig. 4 A, C Early gadolinium enhancement imaging demonstrating a hypointense filling defect at the left ventricular apex. B, D Late gadolinium enhancement imaging demonstrating a large left ventricular apical thrombus and hyperenhancement indicative of endomyocardial fibrosis](image)
the apical thrombus and apical hypertrophy. However, no clear regression of endomyocardial fibrosis was observed. The timeline table is shown in Table 1.

**Literature search strategy**
For the literature review, we searched the PubMed and Embase for relevant studies, including all case reports and case series, published until June 1, 2021. The database was created using the search phrases “Loeffler endocarditis,” “hypereosinophilic syndrome,” and “thrombus.” Studies that described Loeffler endocarditis related to thrombus formation were selected. Patients with specific diseases, including tropical endomyocardial fibrosis, Churg-Strauss syndrome, eosinophilic pneumonia, and clear heart disease combined with thrombus, were excluded. Cases were selected only if sufficient data were available for each case series. Two authors extracted and verified the data independently, and any differences were resolved through discussion. A total of 33 cases were identified. We also used the reference lists of articles published in English for the manual search. The clinical characteristics, complete blood counts, echocardiograms, CMR, treatment monitoring, and clinical follow-up were reviewed.

**Results**
We initially identified 477 articles using the aforementioned search strategy. A total of 33 [6–37] cases of Loeffler endocarditis associated with endoventricular thrombus were found. The epidemiological data, clinical manifestations, diagnostics, treatments, and outcomes are summarized in Table 2. The incidence of embolic stroke was 36.4% among patients with thrombi. The median age of patients was 44 years (IQR: 26–60 years), and the male-to-female ratio was 13:20. At admission, the most common presenting complaint was dyspnea (63.64%), followed by fever (30.30%), nervous system symptoms (18.18%), chest pain (15.15%), fatigue (15.15%), abdominal symptoms (12.12%), cough (6.06%), and palpitations (6.06%). At presentation, 82.0% of cases presented

**Fig. 5** At the 10-month follow-up, early and late gadolinium enhancement imaging demonstrating left ventricular apical thrombus resolution and endomyocardial fibrosis still existing after treatment.
with an unremarkable electrocardiogram, and 24.24% of cases had increased troponin levels. Subsequently, common echocardiographic findings included mitral regurgitation (42.42%) and aortic regurgitation (4%); 15% of patients had the involvement of two valves. A large number of cardiac structures were affected in these patients; however, the ejection fraction was well maintained. Pericardial effusions were observed in 18.18% of patients. Myocardial fibrosis and endoventricular thrombus were usually detected using delayed-enhancement gadolinium imaging. In terms of management, steroid therapy was the most common therapeutic modality (81.8%), and immunosuppression was added in three cases (10%).

In most patients, warfarin was started simultaneously for anticoagulant therapy. Patients who had Loeffler endocarditis with evidence of intracardiac thrombus detected by echocardiography or CMR, and one patient taking warfarin, had bleeding. One (3.1%) patient [26] received heart transplantation, whereas two (6.1%) patients [15, 18] underwent surgical excision of right ventricular (RV) and LV thrombus and fibrosis and mitral valve replacement. Eight patients died from cerebral embolus [28, 34, 37] (37.5%), heart failure [31, 36] (25%), and bacterial sepsis [12, 15, 36] (37.5%). The cause of death was not clarified in one patient. Three patients [18, 26, 31] were readmitted with severe congestive heart failure. Heart failure ($P=0.008$) and the absence of anticoagulation treatment ($P=0.021$) were more common pessimistic outcomes (Table 3). The thrombus was completely resolved in 42.4% of patients and no further events were reported after the hospital discharge follow-up.

### Discussion and conclusion

We described a case presenting with embolic strokes secondary to Loeffler endocarditis with intracardiac thrombus. Also, we provided data based on a series of published cases to summarize the clinical presentation, diagnostic findings, treatment, and outcomes of patients with intracardiac thrombus-proven Loeffler endocarditis. The mortality was found to be high (27.3%) in these recruited patients, and patients with heart failure and those without anticoagulation treatment were associated with poor outcomes.

Cardiac involvement was frequently reported to be related to Loeffler endocarditis in HES, which was characterized by eosinophilic myocardial infiltration and necrosis in the acute necrotic stage. This damage was followed by a chronic fibrotic stage that involved the formation of an intracardiac thrombus with a frequent preference for the apex. This eventually led to restrictive cardiomyopathy and congestive heart failure, which portended an unfavorable prognosis. Our results showed that patients who had Loeffler endocarditis with endoventricular thrombus had a wide age distribution; the disease occurred in patients aged as young as 4 years and as old as 74 years. Women were often more affected than men. Elevated serum troponin levels were found both in the case we described and in most cases we recruited. This might be due to the release of toxic cationic proteins from degranulating eosinophils or pump failure or vascular damage caused by myocardial necrosis [38]. Cardiac markers might be sensitive indicators of persistent eosinophils related to myocardial damage [39]. In addition, echocardiography can provide useful information, such

### Table 1: Time line table from presentation to the last follow up

| Laboratory findings | In hospital | 5 days after treatment | 4-month follow-up | 10-month follow-up |
|---------------------|-------------|-----------------------|-------------------|-------------------|
| **Laboratory findings** |             |                       |                   |                   |
| **White blood cell** (10^9/L) | 20.43       | 11.94                 | 5.5               | 7.85              |
| **Eosinophilia** (10^9/L) | 12.04       | 6.53                  | 0.28              | 0.08              |
| **cTnI** (mg/mL) | 14.10       | 0.35                  | 0.01              | NA                |
| **NT-proBNP** (mg/mL) | 28,700      | 22,300                | 3230              | NA                |
| **ESR** (mm/h) | 79          | NA                    | NA                | NA                |
| **CRP** (mg/L) | 95.4        | NA                    | NA                | NA                |
| **Echocardiography** |             |                       |                   |                   |
| **LVEF, %** | 59          | 64.3                  | 58                | 60                |
| **Thrombus size (mm)** | 16.5*16.4   | 24*18                 | 23*9              | NA                |
| **Treatments** |             |                       |                   |                   |
| **Steroid** | 1 mg/kg/day (intravenous bolus) | 40 mg | NA | NA |
| **Antithrombotic** |             |                       |                   |                   |
| **Rivaroxaban** |             |                       |                   |                   |
| **Warfarin** |             |                       |                   |                   |
| **Warfarin** |             |                       |                   |                   |

WBC, White blood cell; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein; LVEF, left ventricular ejection fraction; NA, not available.
### Table 2: Clinical summary of the 33 cases of loeffler endocarditis with intracardiac thrombus

| Study                        | Sex | Age | Clinical presentation | Eosinophil proportion | Increased troponin I | Valvulopathy/pericardial fluid | Treatment | Surgical intervention | Diagnostic methods | Cardiac dysfunction | Stroke | Evidence of thrombus | Prognosis           |
|------------------------------|-----|-----|-----------------------|-----------------------|----------------------|-------------------------------|-----------|-----------------------|-------------------|-------------------|--------|---------------------|--------------------|
| Lin et al. [6]               | M   | 59  | Dyspnea               | NA                    | Yes                  | AR + MR/No                   | Corticosteroid + Immunosuppresion + Warfarin | No         | Endomyocardial biopsy + TTE | Yes               | No                | L      | Thrombus regression + Doing well |
| Hwang et al. [7]             | M   | 55  | Dyspnea, left-sided weakness | 54.9%                | Yes                  | No / No                      | Corticosteroid + Hydroxyurea + Warfarin | No         | TTE                  | No                | Yes               | L      | Thrombus regression |
| Demetriades et al. [8]       | F   | 57  | Headache, lethargy, and reduced consciousness | 59.1%                | NA                   | No / No                      | Corticosteroid + Warfarin | No         | CMR                  | No                | Yes               | L      | Thrombus regression + Doing well |
| Afzal et al. [9]             | F   | 66  | Dyspnea               | 1.13 k/microL         | NA                   | MR/ No                       | Corticosteroid + Warfarin | No         | CMR                  | No                | No                | L      | Thrombus regression |
| Morgan et al. [10]           | M   | 35  | Dyspnea               | 45%                   | Yes                  | No / Yes                     | Corticosteroid + Warfarin | No         | CMR                  | No                | No                | L      | Thrombus regression |
| Kumar et al. [11]            | M   | 14  | Fever, cough, chest pain | 50.3%                | NA                   | No / No                      | Corticosteroid             | No         | CMR                  | No                | No                | L      | Thrombus regression |
| Kaira et al. [12]            | M   | 61  | Dyspnea               | 55.0%                 | NA                   | MR                           | Corticosteroid + Immunosuppression | No         | CMR                  | Yes               | No                | L      | Died from bacterial sepsis |
| Dufour et al. [13]           | F   | 16  | Fever, chest pain     | NA                    | Yes                  | NA                           | Corticosteroid             | No         | CMR                  | No                | No                | L      | Thrombus regression |
| Kim et al. [14]              | M   | 28  | Headache, dyspnea     | 46.6%                 | NA                   | NA                           | Immunosuppression + imatinib + anti-coagulation | No         | Endomyocardial biopsy | No                | Yes               | L + R  | Thrombus regression |
| Massin et al. [15]           | M   | 12  | Fever, dyspnea        | 71.0%                 | NA                   | MR                           | Corticosteroid + Warfarin | Endomyocardectomy        | CMR               | Yes               | No     | Death (septic shock) |
| Ammirati et al. [16]         | M   | 65  | Palpitations, dyspnea | 18.0%                 | N                    | MR + TR                      | Corticosteroid + anti-coagulation | No         | CMR + Endomyocardial biopsy | Yes               | Yes               | L      | Doing well |
| Casavecchia et al. [17]      | F   | 44  | Fever, dyspnea        | 3.57%                 | NA                   | MR + TR/Y                    | Corticosteroid + Immunosuppression + Warfarin | No         | CMR                  | Yes               | No                | L + R  | Presence of thrombus |
| Wright et al. [18]           | F   | 46  | Fever, dyspnea        | 85.0%                 | NA                   | MR                           | Corticosteroid + interferon alfa | Valve replacement | Endomyocardial biopsy + TTE | Yes               | No                | L      | Thrombus NA Poor prognosis |
| Toshimitsu et al. [19]       | M   | 57  | Numbness of the lower extremities | 55.0%                | NA                   | No / No                      | Corticosteroid + Warfarin | No         | TTE                  | No                | No                | L      | Shrunk thrombus |
| Tai et al. [20]              | F   | 4   | Fever, dyspnea        | 83.0%                 | NA                   | No / No                      | Corticosteroid + Warfarin | No         | CMR                  | No                | No                | R      | Thrombus regression |
| Study         | Sex | Age | Clinical presentation | Eosinophil proportion | Increased troponin I | Valvulopathy/ pericardial fluid | Treatment            | Diagnostic methods | Stroke Evidence of thrombus | Prognosis            |
|--------------|-----|-----|-----------------------|-----------------------|----------------------|-------------------------------|----------------------|---------------------|----------------------------|----------------------|
| Saito et al. [21] | F   | 59  | Fever                 | 30.0%                 | Yes                  | No                            | No/TTR+TIAI+IWM+TIAH  | TTE+CMR             | No                         | L                    |
| Gupta et al. [22] | F   | 17  | Fever, dyspnea        | 30.0%                 | No                   | M+R                          | Corticosteroid+Warfarin   | No                  | No                         | L+R                  |
| Kharabish et al. [23] | M   | 36  | Dyspnea               | 28.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Van et al. [24] | F   | 51  | Dyspnea               | 46.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Lee et al. [25] | M   | 60  | Dyspnea               | 53.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Thaden et al. [26] | F   | 40  | Abdominal pain, diarrhea | 49.1%               | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Koneru et al. [27] | F   | 24  | Nervous system symptoms, chest pain | 49.0%               | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Gross et al. [28] | F   | 12  | Chest pain, dyspnea   | 41.4%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Coelho et al. [29] | M   | 56  | Palpitations, chest pain, dyspnea, fever | 47.0%               | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Chad et al. [30] | F   | 71  | Dyspnea               | 24.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Amin et al. [31] | F   | 74  | Dyspnea               | 64.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Chang et al. [32] | F   | 35  | Left-sided weakness | 29.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Lin-Ch et al. [33] | F   | 67  | Dyspnea, chest pain   | 47.8%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Tanaka et al. [34] | F   | 65  | Dyspnea               | 13.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Uloc et al. [35] | F   | 35  | Abdominal distention  | 13.0%                 | Yes                  | No                            | Corticosteroid+Warfarin   | No                  | No                         | L                    |
| Study                  | Sex | Age | Clinical presentation | Eosinophil proportion | Increased troponin I | Valvulopathy/ pericardial fluid | Treatment                                      | Surgical intervention | Diagnostic methods | Cardiac dysfunction | Stroke | Evidence of thrombus | Prognosis          |
|------------------------|-----|-----|------------------------|-----------------------|----------------------|---------------------------------|----------------------------------------------|-----------------------|---------------------|---------------------|--------|-----------------------|---------------------|
| Case 2 [35]            | F   | 53  | Fever, abdominal pain, dyspnea, cough | 15.0% | NA          | MR + TR/ No | Corticosteroid + Warfarin | No | TTE | N A | No | L + R | Death |
| Salanitri et al. [36]  | F   | 59  | Fatigue, Abdominal pain | 100% | NA          | No/Yes | Corticosteroid + Hydroxyurea | No | Endomyocardial biopsy | N A | No | L + R | Died from septicemia |
| Kocaturk et al. [37]   | M   | 17  | Fever, dyspnea | 45.4% | NA          | No/ No | Corticosteroid + Hydroxyurea | No | TTE | N A | Yes | L | Died from stroke |

TTE, transthoracic echocardiography; MR, mitral regurgitation; TR, tricuspid regurgitation; AR, aortic regurgitation; L, in the left ventricle; R, in the right ventricle; CVA, cerebrovascular accident; NA, not available
as endomyocardial thickening, left and RV thrombus formation, and valvular regurgitation [40]. Of note, Loeffler endocarditis with a small thrombus in the thrombolysis stage might be difficult to diagnose using echocardiography and is sometimes confused with apical hypertrophy, such as that in our case. CMR can clearly identify apical thrombus and diffuse subendocardial fibrosis [41]. Consistent with a significant number of patients, the diagnosis of our case depended on the presence of HES in combination with cardiac involvement on CMR. Hence, if the diagnosis of Loeffler endocarditis with thrombus is under suspicion, CMR is quite informative. Endomyocardial biopsy remains the gold standard but is fraught with risks, such as sampling errors or iatrogenic embolism [42]. Furthermore, the presence of intracardiac thrombus can increase the risk of thromboembolism during an endomyocardial biopsy.

The goals for the treatment of Loeffler endocarditis are to reduce potentially eosinophil-mediated end-organ damage and prevent adverse thrombotic events. Our limited literature showed that 33.3% of patients who had Loeffler endocarditis with intracardiac thrombus developed thromboembolic complications, and the mortality rate was 27.3%. Previous studies showed that thromboembolic disorders associated with Loeffler endocarditis were particularly difficult to control, despite anticoagulation therapy with warfarin, and embolic complications still appeared. One mechanism might involve the release of eosinophilic granular proteins from eosinophils [43], which could neutralize thrombomodulin via electrostatic binding, resulting in thromboembolism. Consistent with the aforementioned findings, thrombus regression occurred in 14 patients (42.4%) after treatment with heparin or vitamin K antagonists both in our reported patient and patients included in this review. The risks of embolic events and mortality in these patients were much higher than those in patients with LVT caused by acute myocardial infarction; however, the rate of thrombus resolution in the recruited patients was relatively lower [44, 45]. The poor outcome suggests that once we identify patients with LVT in clinical practice, HES with cardiac involvement should be taken into consideration. Consistent with our case, several case series demonstrated that most patients who received steroid therapy had hematologically normalized eosinophilia, and cardiac symptoms improved significantly. However, determining the preferred therapy other than corticosteroid therapy as the initial treatment of patients was also the essential step, such as patients with known imatinib-sensitive mutations and myeloproliferative HES. Additional immunosuppressive treatment with cyclophosphamide or azathioprine, as well as other cytotoxic agents or interferon-alpha, is usually reserved for patients with corticosteroid treatment failure. In our study, although one patient received endomyocardial stripping treatment, unfortunately, hypereosinophilia relapsed after 2.5 years. Valve replacement for five patients with severe valvular regurgitation provided considerable benefits. Limited experience with valve replacement/repair and endomyocardial stripping in Loeffler’s study. In addition, consistent with other cases, our study showed that warfarin might have a clear therapeutic benefit in anticoagulation for Loeffler endocarditis with intracardiac thrombus.

Our study was limited by the small number of patients. Also, all data were derived from published cases, leading to publication bias. However, keeping in mind the rarity of Loeffler endocarditis, large-scale prospective or retrospective studies might be more difficult to conduct. Furthermore, the real mortality rate remains difficult to estimate, and cases not critical or with nonspecific symptoms are recorded at a lower rate. Therefore, mortality might be overestimated.

Loeffler endocarditis with intracardiac thrombus is rare, but the mortality is high. Our study highlighted the importance of CMR in establishing the diagnosis and monitoring treatment in Loeffler endocarditis. Early treatment with corticosteroids after excluding secondary causes without delay may be beneficial for these patients. In addition, late recurrence may occur, and long-term follow-up is required.

Table 3 Comparison between those with favorable and poor outcomes (2 cases not available)

|                | Favorable outcomes (n = 19) | Poor outcomes (n = 12) | p value |
|----------------|----------------------------|------------------------|---------|
| Mean age       | 43.1                       | 45.4                   | 0.681†  |
| Male           | 3                          | 9                      | 0.002§  |
| Heart failure  | 5                          | 9                      | 0.008§  |
| Stroke         | 6                          | 4                      | 0.919§  |
| Without steroid| 1                          | 2                      | 0.296§  |
| Without antithrombotic | 3                | 7                      | 0.021§  |

† p value was computed by Independent samples t-test
§ p value was computed by Fisher’s exact test

Abbreviations
HES: Hypereosinophilic syndrome; LV: Left ventricular; RV: Right ventricular.

Acknowledgements
Not applicable.

Authors’ contributions
QZ cared for the patient and drafted the manuscript. ZZ performed the literature search and analysed the data, DS critically revised the manuscript, and WZ provided consultation and coordination of the manuscript. All authors reviewed and approved the final manuscript.
Funding
This work was supported by grants from Science and Technology of Jilin Province (2021020419197Y and 20200801076GH). The funding body had no role in the design or writing of the study.

Availability of data and materials
All the data discussed in the manuscript are included in this published article.

Declarations

Ethics approval and consent to participate
This case report was approved by the Medical Ethics Committee of the China-Japan Union Hospital of Jilin University. The patient consented to participate in the study.

Consent for publication
Written informed consent was obtained from the patients for publication.

Competing interests
The authors have no conflicts of interest to disclose.

Received: 7 October 2021 Accepted: 21 December 2021

Published online: 28 December 2021

References
1. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-12.e9.
2. Alam A, Thampli S, Saba SG, Jermyn R. Loeffler endocarditis: a unique presentation of right-sided heart failure due to eosinophil-induced endocardial fibrosis. Clin Med Insights Case Rep. 2017;10:1179547617723643. https://doi.org/10.1177/1179547617723643.
3. Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac diagnosis and management. Heart. 2016;102(2):100-6.
4. Podjasek JC, Butterfield JH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res. 2013;37(4):392-5.
5. Cañiero AJ, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48, 2648a-2648d. https://doi.org/10.1093/eurheartj/eht210.
6. Lin WC, Huang KC, Hsiung MC, Feng AN. Loeffler's endocarditis in a patient with a new diagnosed Churg-Strauss syndrome (CSS): a case report. Caspian J Intern Med. 2021;12(1):107-10. https://doi.org/10.22088/cjim.12.1.1107.
7. Hwang JW, Kim H, Cho SW, Shin YC, Kim HS, Cho YJ, et al. Idiopathic hypereosinophilic syndrome with intracardiac atypical linear-shaped and floating thrombus presenting as embolic cerebral infarction. J Cardiol Cases. 2020;2020(5):193-7.
8. Demetreides P, Speke L, Wilson L, Khan JN. When multimodality cardiac imaging saves the day: rare cause of embolic strokes. BMJ Case Rep. 2020;2020(1):e232786. https://doi.org/10.1136/bcr-2019-232786.
9. Atfal S, Ahmed T, Saleem T, Chan A. Loeffler's endocarditis and the diagnostic utility of multimodality imaging. Cureus. 2020;12(8): e10061. https://doi.org/10.7759/cureus.10061.
10. Morgan H, Zaidi A, Anderson R, Goodfellow R, Ellis G. New breathlessness in a young patient with rheumatoid arthritis. Br J Hosp Med (Lond). 2019;80(10):612-3.
11. Kumar P, Chandrashekhara SH, Kumar S, Malhi AS. Loeffler's endocarditis with isolated left ventricular involvement on cardiac MRI. BMJ Case Rep. 2019;2019(12):e227642. https://doi.org/10.1136/bcr-2018-227642.
12. Kalra DK, Park J, Henu M, Goldberg A. Loeffler endocarditis: a diagnosis made with cardiovascular magnetic resonance. J Cardiovasc Imaging. 2019;27(1):70-2.
infarction, and left hydranencephaly: a case report. Acta Neurol Taiwan. 2009;18(3):207–12.

34. Tanaka H, Kawai H, Tatsumi K, Kataoka T, Onishi T, Nose T, et al. Surgical treatment for Löeffler's endocarditis with left ventricular thrombus and severe mitral regurgitation: a case report. J Cardiol. 2006;47(4):207–13.

35. Uçar O, Gölbazi Z, Yıldırım N. Two cases of endomyocardial disease with hypereosinophilia in Turkey. Eur J Echocardiogr. 2005;6(5):379–81.

36. Salantri GC. Endomyocardial fibrosis and intracardiac thrombus occurring in idiopathic hypereosinophilic syndrome. AJR Am J Roentgenol. 2005;184(5):1432–3.

37. Kocaturk H, Yilmaz M. Idiopathic hypereosinophilic syndrome associated with multiple intracardiac thrombi. Echocardiography. 2005;22(8):675–6.

38. Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, Korber T, et al. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol. 2010;99(7):419–27.

39. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101(12):4660–6.

40. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000;86(1):110–3.

41. Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol. 2008;126(3):e50–2.

42. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiological, and therapeutic considerations. Ann Intern Med. 1982;97(1):78–92.

43. Mukai HY, Ninomiya H, Ohtani K, Nagasawa T, Abe T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Br J Haematol. 1995;90(4):892–9.

44. Zhang Z, Si D, Zhang Q, Qu M, Yu M, Jiang Z, et al. Rivaroxaban versus Vitamin K Antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction. Heart Vessels. 2021. https://doi.org/10.1007/s00380-021-01921-z.

45. Chen PF, Tang L, Yi JL, Pei JY, Hu XQ. The prognostic effect of left ventricular thrombus formation after acute myocardial infarction in the contemporary era of primary percutaneous coronary intervention: a meta-analysis. Eur J Intern Med. 2020;73:43–50.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.